Hodgkin's Lymphoma
122
6
8
70
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
36 trials with published results (30%)
Research Maturity
70 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
23.0%
28 terminated out of 122 trials
71.4%
-15.1% vs benchmark
7%
8 trials in Phase 3/4
51%
36 of 70 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 70 completed trials
Clinical Trials (122)
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Biology Studies of Hematologic Cancers
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Communication Skills Intervention to Promote Transition Into Survivorship
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma